Nov 02, 2020 8:00 am EST CymaBay Therapeutics Announces an Oral Late-Breaking Presentation of Results from the ENHANCE Global Phase 3 Study Evaluating Seladelpar for Primary Biliary Cholangitis at The Liver Meeting® 2020
Oct 30, 2020 4:31 pm EDT CymaBay Therapeutics to Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020
Oct 01, 2020 8:00 am EDT CymaBay Therapeutics to Present Data from its Phase 2 Study of Seladelpar in Patients with NASH at The Liver Meeting® 2020
Aug 27, 2020 8:00 am EDT CymaBay Therapeutics Presents Positive Final Results From 52-Week Phase 2 Study in Primary Biliary Cholangitis at The Digital International Liver Congress™ 2020
Aug 20, 2020 8:00 am EDT CymaBay Therapeutics Announces Presentations During The Digital International Liver Congress™ 2020
Aug 10, 2020 4:01 pm EDT CymaBay Reports Second Quarter 2020 Financial Results and Provides Corporate Update
Aug 03, 2020 4:01 pm EDT CymaBay Therapeutics to Report Second Quarter 2020 Financial Results on Monday, August 10, 2020
Aug 03, 2020 7:00 am EDT CymaBay Announces Positive Topline Results from ENHANCE for Seladelpar in Patients with Primary Biliary Cholangitis